A practical reference on circadian clock: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-02 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Prolargin is a protein that in humans is encoded by the PRELP gene. The protein encoded by this gene is a leucine-rich repeat protein present in connective tissue extracellular matrix. This protein functions as a molecule anchoring basement membranes to the underlying connective tissue. This protein has been shown to bind type I collagen to basement membranes and type II collagen to cartilage. It also binds the basement membrane heparan sulfate proteoglycan perlecan. This protein is suggested to be involved in the pathogenesis of Hutchinson–Gilford progeria (HGP), which is reported to lack the binding of collagen in basement membranes and cartilage. Alternatively spliced transcript variants encoding the same protein have been observed.
=== Selection for Tavistock === In March 1965, Heseltine applied to be candidate for the safe Conservative seat of Tavistock in Devon, where the incumbent MP had announced his retirement two months earlier. Of the 51 applicants, 14 were considered, six of whom had local connections. Heseltine reached the final short list of three, the others being a dairy farmer in a senior position at the Milk Marketing Board (thought to be the favourite), and a local authority lawyer, who later recalled that on the train down from London Heseltine kept jumping out at every stop to check that his magazines were on display at the station newsagents. Heseltine had already spent several days driving round talking to locals and had ordered a year's worth of back copies of Tavistock's two weekly papers. Such effort is nowadays common in Parliamentary selections but was unusual at the time. He was selected by a clear majority of the Tavistock Conservative Association's Finance and General Purposes Committee (which contained between 100 and 120 people). Heseltine was picked in part as a young, dynamic candidate who could face the challenge of the resurgent Liberal Party in the West Country, where Jeremy Thorpe, Peter Bessell and Mark Bonham Carter had recently won seats. The Liberals had halved the Conservative majority at Tavistock in 1964. Trouble then arose at his adoption by a full general meeting of the Conservative Association, which should have been a formality.
=== Tau in Frontotemporal Lobar Degeneration (FTLD) === The tau protein is one of the most common aggregated proteins in frontotemporal lobar degeneration (FTLD), the pathology underlying FTD disorders, the other being TDP-43. While protein aggregation underlies FTLD tauopathies, the specific tau isoforms present and the morphology of the aggregates vary across subtypes. FTLD tauopathies are predominantly associated with the 3R and 4R tau isoforms. The “Pick bodies” characteristic of the FTLD tauopathy known as “Pick’s disease” is associated with 3R tau. Progressive supranuclear palsy (PSP) and corticobasal syndrome/degeneration (CBS/CBD), meanwhile, are associated with the 4R isoform. There is evidence that a ratio of 3R and 4R tau is essential for preventing neurodegeneration, and that alterations in this ratio are believed to drive FTLD and related disorders without requiring co-occurrence with other pathologies. FTD-tau appears to be sporadic in the majority of people diagnosed, but researchers do not yet fully understand the pathological mechanisms. Inherited pathogenic variants in the MAPT gene, however, are responsible for a fraction of people diagnosed with FTD-tau. Within and between families, FTD due to MAPT presents with significant heterogeneity in the symptoms that may be present, underscoring the possibility for genetic modifiers and environmental factors to influence clinical presentation. Intronic variants in MAPT, and most variants in exon 10, affect the 3R/4R tau ratio, contributing significantly to the development of FTLD pathology.
Sources: en.wikipedia.org
== Role in the immune system == In addition to their role as UV radical scavengers, melanocytes are also part of the immune system, and are considered to be immune cells. Although the full role of melanocytes in immune response is not fully understood, melanocytes share many characteristics with dendritic cells: branched morphology; phagocytic capabilities; presentation of antigens to T-cells; and production and release of cytokines. Although melanocytes are dendritic in form and share many characteristics with dendritic cells, they derive from different cell lineages. Dendritic cells are derived from hematopoietic stem cells in the bone marrow. Melanocytes on the other hand originate from neural crest cells. As such, although morphologically and functionally similar, melanocytes and dendritic cells are not the same. Melanocytes are capable of expressing MHC Class II, a type of MHC expressed only by certain antigen presenting cells of the immune system, when stimulated by interactions with antigen or cytokines. All cells in any given vertebrate express MHC, but most cells only express MHC class I. The other class of MHC, Class II, is found only on "professional" antigen presenting cells such as dendritic cells, macrophages, B cells, and melanocytes. Importantly, melanocytes stimulated by cytokines express surface proteins such as CD40 and ICAM1 in addition to MHC class II, allowing for co-stimulation of T cells. In addition to presenting antigen, one of the roles of melanocytes in the immune response is cytokine production.
The government's defence spending increased from R$30 million, 8.5% of the national budget in 1971 to 1972, to R$400 m in 1978 to 1979, 47% of the national budget. In 1980, the post-independence government of Zimbabwe inherited a US$500 million national debt.
Caesium-137 has been used as a tracer in hydrologic studies, analogous to the use of tritium. Small amounts of caesium-134 and caesium-137 were released into the environment during nearly all nuclear weapon tests and some nuclear accidents, most notably the Goiânia accident and the Chernobyl disaster. As of 2005, caesium-137 is the principal source of radiation in the zone of alienation around the Chernobyl nuclear power plant. Its chemical properties as one of the alkali metals make it one of the most problematic of the short-to-medium-lifetime fission products because it easily moves and spreads in nature due to the high water solubility of its salts, and is taken up by the body, which mistakes it for its essential congeners sodium and potassium.
Sources: en.wikipedia.org
== Signs and symptoms == ED is characterized by the persistent or recurring inability to achieve or maintain an erection of the penis with sufficient rigidity and duration for satisfactory sexual activity. It is defined as the "persistent or recurrent inability to achieve and maintain a penile erection of sufficient rigidity to permit satisfactory sexual activity for at least 3 months."
The Paleolithic overlaps with the Pleistocene epoch of geologic time. Both ended 12,000 years ago although the Pleistocene started 2.6 million years ago, 700,000 years after the Paleolithic's start. This epoch experienced important geographic and climatic changes that affected human societies. During the preceding Pliocene, continents had continued to drift from possibly as far as 250 km (160 mi) from their present locations to positions only 70 km (43 mi) from their current location. South America became linked to North America through the Isthmus of Panama, bringing a nearly complete end to South America's distinctive marsupial fauna. The formation of the isthmus had major consequences on global temperatures, because warm equatorial ocean currents were cut off, and the cold Arctic and Antarctic waters lowered temperatures in the now-isolated Atlantic Ocean. Most of Central America formed during the Pliocene to connect the continents of North and South America, allowing fauna from these continents to leave their native habitats and colonize new areas. Africa's collision with Asia created the Mediterranean, cutting off the remnants of the Tethys Ocean. During the Pleistocene, the continents were essentially at their modern positions; the tectonic plates on which they sit have probably moved at most 100 km (62 mi) from each other since the beginning of the period. Climates during the Pliocene became cooler and drier, and seasonal, similar to modern climates. Ice sheets grew on Antarctica.
==== Heart attack ==== On 21 June 1993, Heseltine suffered a serious heart attack in Venice (especially worrying as Heseltine was sixty, and his father had died of a heart attack aged fifty-five). The pains had already stopped by the time he reached hospital. Heseltine was shown looking unwell and using a wheelchair – in fact the result of gout in his foot from the medication which he was taking. He took four months off from work, and did not make a speech at the party conference in October 1993, instead amusing the audience by appearing on the platform and performing mock exercises with his arms. There were concerns about his ability to remain in government. In 1994 Chris Morris jokingly implied on BBC Radio 1 that Heseltine had died, and persuaded MP Jerry Hayes to broadcast an on-air tribute. Morris was subsequently suspended.
Variable pathlength absorption spectroscopy uses a determined slope to calculate concentration. As stated above this is a product of the molar absorptivity and the concentration. Since the actual absorbance value is taken at many data points at equal intervals, background subtraction is generally unnecessary. The image on the right is a linear plot showing both the background corrected data and the raw data. This shows that the absorbance values on the plot are offset by an equal amount and the slope of the two plots are equal. Thus, the concentration calculated from the two plots is equal. Other scalar components that contribute to the absorbance of a given sample like contaminants on the cuvette or a different cuvette material also are averaged out during the slope measurement. The technique is also applicable for in line measurements for TFF and chromatography applications.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.